Arrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on Monday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to release its earnings data after the market closes on Monday, February 5th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative net margin of 109.46% and a negative return on equity of 38.10%. On average, analysts expect Arrowhead Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $6.12 on Monday. Arrowhead Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $6.75. The stock has a market capitalization of $457.95, a PE ratio of -13.02 and a beta of 1.79. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.63 and a current ratio of 3.63.

A number of brokerages have recently issued reports on ARWR. ValuEngine raised Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective on the stock in a research note on Monday, November 27th. BidaskClub cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 16th. Finally, B. Riley began coverage on Arrowhead Pharmaceuticals in a research note on Friday, January 5th. They issued a “neutral” rating and a $3.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $3.13.

In related news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 1st. The stock was sold at an average price of $3.69, for a total value of $73,800.00. Following the sale, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.57% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply